Clinical trial of TEW-7197 starts its first step.
Jul 17, 2014EVENTSHit 2187
MedPacto, Inc. completed the fully executed site contract for one of three clinical sites for TEW-7197 in the USA on 18th July, 2014 (NCT02160106). TEW-7197 is the forefront asset of MedPacto's oncology pipeline and it is for cancer patients of solid tumors. The phase 1 trial is planned to complete in April of 2016.
|Next||The first dosing of TEW-7197 in a cancer patient in the USA|
|Previous||MedPacto gets an approval of IND for TEW-7197 from US FDA|